Cell Biotech Showcases DUOLAC at SupplySide Global 2025, North America’s Largest Health & Nutrition Expo

Cell Biotech announced its participation at SupplySide Global 2025 (SSG 2025), the largest health and nutrition trade show in North America, together with its flagship probiotic brand DUOLAC.

At the event, the company highlighted DUOLAC’s core proprietary technology — the Dual Coating system — and its K-Probiotics registered as FDA GRAS (Generally Recognized As Safe), underscoring its enhanced global competitiveness.

SSG 2025 took place from October 29 to 30 (local time) at the Mandalay Bay Convention Center in Las Vegas, USA, gathering over 1,600 global exhibitors and 20,000 visitors annually.

The exhibition covers the entire spectrum of the health and nutrition industry — from functional food ingredients and dietary supplements to pet nutrition, manufacturing equipment, and OEM services — offering a comprehensive look at the latest global trends and innovations.

At its independent booth, Cell Biotech introduced its 4th-generation Dual Coating technology, developed to maximize probiotic survival rates.

This technology has been proven to increase bacterial survival rates by up to 91.6%, and clinical studies confirmed that DUOLAC’s coated probiotics demonstrated up to 221 times higher intestinal survivability compared to uncoated strains.

The company also emphasized its achievement as the world leader in the number of probiotic strains registered under FDA GRAS, reinforcing its reputation for global safety and quality excellence.

As one of the most rigorous safety recognition programs by the U.S. Food and Drug Administration (FDA), the GRAS certification represents a high standard of credibility and a significant barrier to entry in the global probiotic market.

Throughout the exhibition, the Cell Biotech booth attracted business representatives from around the world, engaging in active discussions about DUOLAC product collaborations and potential global partnerships.

Building on its consistent participation in major global health exhibitions such as Vitafoods Europe and Vitafoods Asia, Cell Biotech aims to further strengthen its B2B expansion in North America through scientifically validated data and clinical evidence supporting its K-Probiotics.

A Cell Biotech spokesperson commented,

“Through this exhibition, we were able to once again showcase the technological excellence of our leading Korean probiotic brand DUOLAC and the superior quality of K-Probiotics to the global market.

Building on our record number of FDA GRAS registrations and innovative Dual Coating technology, we plan to accelerate our entry into the U.S. market and lead the globalization of K-Probiotics.”

Meanwhile, DUOLAC recently launched a new advertising campaign featuring actor Son Seok-gu, titled “DUOLAC, 221 Times Stronger Probiotics.”

The campaign aims to raise awareness about the importance of intestinal survivability — shifting consumer perception from simply focusing on probiotic counts to understanding what truly defines a “good probiotic.”